Dyne Therapeutics, Inc. (DYN) – What Are Analysts Saying About This Stock?

Posted by Francis Steltz on Oct 18th, 2026

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) has been given an average rating of “Moderate Buy” by the sixteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $33.07.

A number of equities research analysts recently commented on the company. TD Cowen assumed coverage on Dyne Therapeutics in a report on Friday, June 26th. They issued a “buy” rating for the company. HC Wainwright decreased their price target on Dyne Therapeutics from $50.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, September 30th. Stifel Nicolaus set a $37.00 price target on Dyne Therapeutics in a research note on Wednesday, September 30th. Morgan Stanley dropped their target price on Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating for the company in a report on Wednesday, September 9th. Finally, Wall Street Zen downgraded Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st.

Read Our Latest Report on DYN

Insiders Place Their Bets

In other Dyne Therapeutics news, insider Douglas Kerr sold 3,745 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $24.35, for a total value of $91,190.75. Following the sale, the insider owned 163,854 shares of the company’s stock, valued at approximately $3,989,844.90. This trade represents a 2.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Cox sold 5,658 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the completion of the sale, the chief executive officer directly owned 357,507 shares in the company, valued at $6,749,732.16. This trade represents a 1.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 2,598,706 shares of company stock valued at $65,432,671 over the last ninety days. Company insiders own 9.46% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Dyne Therapeutics during the 2nd quarter worth $275,500,000. Jupiter Topco LLC acquired a new position in shares of Dyne Therapeutics during the 2nd quarter valued at $266,634,000. Perceptive Advisors LLC boosted its position in shares of Dyne Therapeutics by 34.2% during the 1st quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock worth $84,646,000 after purchasing an additional 1,189,895 shares in the last quarter. Armistice Capital LLC boosted its holdings in Dyne Therapeutics by 6.1% in the fourth quarter. Armistice Capital LLC now owns 3,249,708 shares of the company’s stock worth $63,564,000 after acquiring an additional 185,708 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. grew its position in Dyne Therapeutics by 16.0% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,153,082 shares of the company’s stock valued at $61,674,000 after purchasing an additional 434,977 shares during the period. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Trading Down 6.8%

DYN stock opened at $14.25 on Friday. Dyne Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $27.31. The stock has a market capitalization of $2.66 billion, a price-to-earnings ratio of -4.28 and a beta of 1.12. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The business has a fifty day moving average price of $20.49 and a 200 day moving average price of $20.37.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last announced its earnings results on Wednesday, July 29th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). Analysts expect that Dyne Therapeutics will post -3.59 EPS for the current fiscal year.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing genetic medicines for serious neuromuscular diseases. The company’s research is centered on its FORCE platform, which is designed to use targeted antibodies to deliver oligonucleotide-based therapies to skeletal muscle and other relevant tissues.

Dyne’s development programs include DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.